Markets:

Overview

News

Currencies

International

Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

6.420 -0.610 (-8.68%)

Streaming Delayed Price Updated: 1:39 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗

August 28, 2023

Via Benzinga

Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

$8M Bet On Vicarious Surgical? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗

August 10, 2023

The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Earnings Outlook For Xeris Biopharma Holdings ↗

August 07, 2023

Via Benzinga

Xeris Pharmaceuticals's Earnings Outlook ↗

March 07, 2023

Via Benzinga

Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline

August 08, 2023

Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...

Via Newsfile

Xeris Biopharma Reports Second Quarter 2023 Financial Results

August 08, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

August 01, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Ships One Millionth Gvoke® Unit

July 31, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday ↗

June 29, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

June 21, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Participate at the Jefferies Healthcare Conference

June 01, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Reports First Quarter 2023 Financial Results

May 09, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For May 9, 2023 ↗

May 09, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.

Via Benzinga

Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

May 02, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

April 18, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™

March 30, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Appoints Ricki Fairley to Board of Directors

March 29, 2023

From Xeris Biopharma Holdings

Via Business Wire

Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

March 08, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For March 8, 2023 ↗

March 08, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

Via Benzinga

Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

February 23, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

February 02, 2023

From Xeris Biopharma, Inc.

Via Business Wire

Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

January 30, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference

January 05, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

January 05, 2023

On Thursday, 63 companies set new 52-week lows.

Via Benzinga

Xeris Biopharma Updates Its Outlook For 2022

January 05, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

January 04, 2023

On Wednesday, 35 companies reached new 52-week lows.

Via Benzinga

Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

December 15, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab

November 23, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events

November 09, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.